91ÉçÇø

Event

MDC Semi-Finals 2019 Health Sciences Track

Tuesday, February 19, 2019 09:00to16:00
Bronfman Building Room TBD, 1001 rue Sherbrooke Ouest, Montreal, QC, H3A 1G5, CA

The teams that make it past the Semi-Finals will be invited to the Finals round of the competition, scheduled to take place on March 27th, 2019.

The competition will culminate with the 91ÉçÇø Dobson Cup 2019 Awards Ceremony, taking place on April 4th, 2019, where over $150,000 in seed funding will be awarded to the most promising startups.

now to find out who wins – tickets sell out fast!


91ÉçÇø Dobson Cup 2019: Announcing the Startups Pitching in the Semi-Finals

Health Sciences Track

1. :Ìý Arkangel is a health guardian design to prevent chronic diseases. It’s like Siri for health. We use AI to automate a medical program developed at the US. Center for Disease Control to prevent diabetes.

2. : We’re building a $1000 portable brain imaging scanner for point-of-care diagnosis in ambulances, field hospitals, sports teams, and patient rooms.

3. BetaSense: We are a dynamic team that aims to tackle invasive problems in nuclear medicine and give them a Non-Invasive solution to enable personalized medicine in a greater number of clinics.

4. C-Marker: C-Marker is a composite disclosing agent that was developed at Professor Tamimi’s lab at the Faculty of Dentistry, 91ÉçÇø. C-Marker is a new material that will help dentists identify the margins of white fillings and facilitate their complete removal without removing sound tooth structure.

5. : We are an AI-powered digital platform aiming to improve recovery outcomes of people living with mental illnesses.

6. Denovogen: Denovogen is a biomedical technology company focused on the design and commercialization of innovative medical devices. Our first product aims to improve communication and visualization in the surgical theatre.

7. eRA Rehab: Harnessing the power of smartphones to create a strong ecosystem between customers and clinicians to enhance the recovery process.

8. : FlůID Inc. is dedicated to developing non-ionizing molecular imaging methods (without radioactivity) reducing the time and costs associated with advancing potential clinical candidates to studies in man.

9. : Gynoteck is a leading innovator in medical diagnostics, preventative, and treatment methods for women’s health. We aim to personalize medicine as every woman is different.

10. LFANT: LFANT is a company dedicated to the development of safe, reliable, and readily available commercial kits for the self-administered detection of STIs in the interest of public health and awareness.

11. : MicroPredictome aims to create licensable AI algorithms to predict the risk of different gastrointestinal diseases based on sequencing data from the bacterial population of the human gut.

12. Modus Inc.: Modus Inc would be a cutting-edge facility capable of developing and validating affordable blood-based biomarkers for brain diseases (much like Ancestry.ca tests saliva for DNA) and provide a report on the degree to which one is destined for AD – Yes, No and how much. Continuing to research methods, discoveries or techniques from Life Sciences to bring to commercial markets.

13. : We are developing the next-generation of protein-based blood tests. Our platform promises to unlock unprecedented efficiencies in drug development, biomarker discovery, and ultimately, precision medicine.

14. Tracheo-Sure: Tracheo-Sure aims to revolutionize endotracheal intubation for airway management by creating a surgical device to improve speed, efficiency, and patient safety while reducing overall healthcare cost and improving medical education.

15. :ÌýVitalTracer is a medical smartwatch that measures all vital signs continuously, including cuffless blood pressure. Our mission is to provide quality solutions that accurately capture vital signs to keep users alert and aware of their health at all times. Our solutions will revolutionize the relationship between patients and caregivers by creating an easy and accurate way to track, record and share all measured parameters.

Back to top